Cyril Amarchand Mangaldas advised J.P. Morgan Services India Private Limited
The transaction marks a significant real estate leasing deal supporting JPM’s India operations.
The transaction marks a significant real estate leasing deal supporting JPM’s India operations.
The transaction involved a 50:50 joint investment to establish a leading independent distributor of engineering plastics in India, strengthening ALBIS’s footprint in the Indian market.
The transaction involved leasing both the East and West Wings of Building No. 1, covering over 6 lakh sq. ft. of office space along with parking and allied facilities.
The transaction involved a long-term lease of the Taurus-4 (North Tower) building, including extensive parking facilities, reinforcing ARM’s operational presence in India’s technology hub.
The transaction involved the transfer of 100% shareholding through share purchase agreements, marking a key infrastructure asset monetisation deal.
The merger involves equity issuance to Orient shareholders, cancellation of cross-holdings, and regulatory approvals, representing a key consolidation move in India’s cement and infrastructure sector.
The IPO, which saw over 39× subscription, marked a landmark transaction in India’s equity capital markets and commenced trading on the BSE and NSE on 19 December 2025.
The merger involves equity issuance by Ambuja to ACC shareholders and results in a post-merger change in Ambuja’s shareholding structure, marking a significant consolidation in India’s cement sector.
The transaction, India’s largest disclosed private credit deal in the telecom sector, was structured to support Vodafone Idea Limited’s capital expenditure and business growth.
The transaction was undertaken in compliance with SEBI ICDR Regulations and marks one of the largest rights issues in the Indian capital markets.
The transaction involves multidisciplinary legal advice spanning M&A, employment, tax, data privacy, and equity compensation matters.
The transaction resulted in a change of control and triggered a mandatory open offer under SEBI takeover regulations, alongside structured acquisition financing.
The IPO comprised a fresh issue and an offer for sale, with IFC divesting part of its shareholding. Nephrocare’s equity shares were listed on Indian stock exchanges on 17 December 2025.
The investment, announced on November 25, was made by funds managed by KKR along with participation from new investor PSP Investments of Canada, reinforcing confidence in India’s education sector.
The transaction strengthens Lighthouse Learning’s position as a leading Indian education services provider. CAM advised on corporate, diligence, real estate, employment, disputes, finance, and competition aspects of the deal.
The transaction marks the first phase of consolidating L&T’s real estate assets into a unified entity positioned for India’s growing property market.
Cyril Amarchand Mangaldas advised Serum Institute on the proposed sale of its stake in Biocon Biologics to Biocon and the simultaneous subscription of shares in Biocon Limited through a share swap transaction valued at ₹2,250 crore. The deal marks a significant restructuring in India’s biopharmaceutical sector.
CAM advised Ashoka Buildcon Limited on Macquarie’s ~₹1,715 crore exit from its group entities, providing end-to-end transactional support on the divestment of stakes in Ashoka Concessions Limited and Jaora—Nayagaon Toll Road Company Private Limited.
The Panel upheld Coinswitch’s claim on all three UDRP criteria, finding confusing similarity, lack of legitimate rights, and bad faith registration and use.
The deal involves an initial USD 2 billion equity commitment, with an additional USD 4—5 billion planned through debt, marking one of India’s largest private equity investments in the digital infrastructure sector.